NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Rotarix®, an oral, two-dose rotavirus candidate vaccine to prevent rotavirus gastroenteritis in infants, received a favorable recommendation from the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC). AVANT licensed the technology for Rotarix® to GlaxoSmithKline in 1997 for worldwide commercialization. Severe, dehydrating gastroenteritis occurs primarily among children aged three to 35 months. The committee’s favorable recommendation, although not binding, will be considered by the FDA in its review of the Biologics License Application (BLA) for the candidate vaccine, which is currently underway.
